Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor
US10898570B2 · kind B2 · utility
2Cited by
18References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2017 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | Dec 20, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.